Selective Serotonin-Reuptake Inhibitor–Induced Movement Disorders

Gerber, Patricia; Lynd, Larry D.

doi:10.1345/aph.17302

Cited by 226 publications

(134 citation statements)

References 34 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…It may also explain the increased incidence of depression preceding the diagnosis of PD, because of the fact that pathophysiological compensatory mechanisms are already in action long before clinical symptoms become apparent (Leentjens et al, 2003b). Finally, it may provide an explanation for the exacerbation of extrapyramidal symptoms that occur in some PD patients treated with selective serotonin reuptake inhibitors (SSRIs) (Leo, 1996;Gerber and Lynd, 1998). In spite of the fact that this hypothesis was launched in 1984, to date it has not been experimentally verified.…”

Section: Introductionmentioning

confidence: 99%

The Serotonergic Hypothesis for Depression in Parkinson's Disease: an Experimental Approach

Leentjens

Scholtissen

Vreeling

et al. 2005

Neuropsychopharmacol

View full text Add to dashboard Cite

The serotonergic hypothesis for depression in Parkinson's disease (PD) states that the reduced cerebral serotonergic activity that occurs in PD constitutes a biological risk factor for depression. The aim of our study was to assess the serotonergic hypothesis of depression in PD patients using an experimental approach. In a double-blind, randomized order, placebo-controlled crossover design, the response on the Profile of Mood States (POMS) questionnaire to acute tryptophan depletion (ATD) was studied in 15 PD nondepressed patients and 15 control subjects, without a prior personal or family history of depression. PD patients had lower (worse) baseline scores on the sadness, fatigue and vigor subscales of the POMS, in both ATD and the placebo condition, but not on the tension and anger subscales. There was however neither a significe between group effect, nor significe within-group effect due to ATD. We could find no evidence of a specific serotonergic vulnerability of PD patients for depression. Therefore, our results do not support the serotonergic hypothesis for depression in PD.

show abstract

Section: Introductionmentioning

confidence: 99%

The Serotonergic Hypothesis for Depression in Parkinson's Disease: an Experimental Approach

Leentjens

Scholtissen

Vreeling

et al. 2005

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…Двойных слепых исследований влия-ния пероральных медикаментов на эти симптомы не про-водилось. Ряд лекарственных препаратов, влияющих на некоторые проявления дистонии или сопутствующие заболевания, например нейролептики или антидепрес-санты из группы селективных ингибиторов серотонина, могут ухудшать течение дистонии [62].…”

Section: лечениеunclassified

Focal Dystonias: Non-Motor Symptoms and Comorbidities

Толмачёва¹

2017

Med. sov.

View full text Add to dashboard Cite

Дистония является распространенным экстрапирамидным заболеванием. Для нее характерны как моторные, так и немоторные проявления, к которым относятся боль, сенсорные нарушения, избыточная двигательная активность. Обсуждается вклад тревож-ных и депрессивных расстройств, нарушений сна в течение фокальной дистонии. Нередко именно немоторные проявления являются начальными симптомами дистонии. В ряде случаев немоторные проявления можно выделить в самостоятельные заболевания, которые сопутствуют дистоническому гиперкинезу и способствуют ухудшению качества жизни таких больных. Лечение немоторных симптомов позволит повысить эффективность терапии дистонии, а также повлиять на течение заболевания.Ключевые слова: дистония, немоторные симптомы, коморбидность, лечение. V.A. TOLMACHYOVA, PhD in medicine, Sechenov First Moscow State Medical University FOCAL DYSTONIAS: NON-MOTOR SYMPTOMS AND COMORBIDITIESDystonia is a common extrapyramidal disease. It is characterized by both motor and non-motor manifestations, which include pain, sensory disorders and excessive physical activity. The contribution of disturbing and depressed disorders, sleep disorders during the focal dystonia has been discussed. It is often the non-motor manifestations that are the initial symptoms of dystonia. In some cases, unmotorized manifestations can be isolated diseases that accompany dystonic hyperkinesis and contribute to the deterioration of the quality of life of such patients. Treatment of nonmotor symptoms will improve the effectiveness of dystonia therapy as well as affect the course of the disease.

show abstract

“…In complimation of the articles, akathisia is reported as the most extrapyramidal side effect in relation with SSRI after dystonia. 68,69 Gerber et al 69 have identified 127 extrapyramidal symptoms induced with SSRI. 19 of these symptoms are described as dystonia.…”

Section: Antidepressants Tricyclic Antidepressant Agents (Tcas)mentioning

confidence: 99%

Psychotropic Drugs and Ocular Side Effects

Sönmez¹,

Aykan²

2013

Tjo

View full text Add to dashboard Cite

Sum maryNowadays the number of patients using the types of drugs in question here has significantly increased. A study carried out in relation with the long term use of psychotropic drugs shows that the consumption of this group of drugs has substantially increased in terms of variety and quantity. This compilation is arranged in accordance with the ocular complications of psychotropic drugs in long term treatment profile of numerous patients to the results of related literature review. If the doctor and the patients are informed about the eye problems related to the use of psychotropic drugs, potential ocular complications can be easily prevented, supervised and controlled and can even be reversed. (

show abstract

Selective Serotonin-Reuptake Inhibitor–Induced Movement Disorders

Cited by 226 publications

References 34 publications

The Serotonergic Hypothesis for Depression in Parkinson's Disease: an Experimental Approach

The Serotonergic Hypothesis for Depression in Parkinson's Disease: an Experimental Approach

Focal Dystonias: Non-Motor Symptoms and Comorbidities

Psychotropic Drugs and Ocular Side Effects

Contact Info

Product

Resources

About